In addition to his appointment, Blaser will join the company’s board of directors on May 15, when it will expand from 10 to 11 members.
“We are excited to welcome Brian as our new president, CEO and director,” Board Chair Kenneth Buechler said in a news release. “Brian brings over 25 years of senior leadership experience in the in-vitro diagnostics industry, including seven years of full responsibility for Abbott’s global diagnostics business. His proven track record of executing transformational strategies to streamline operations and driving revenue growth to dramatically improve profitability makes him an ideal leader to guide QuidelOrtho through its next phase of growth.”
Blaser was most recently EVP of diagnostic products at Abbott. He oversaw the global diagnostics organization, including core laboratory, point of care, rapid diagnostics and molecular diagnostics businesses. Before that, he held varying strategic, operational and diagnostic roles at Abbott and leadership roles at the Ortho Clinical Diagnostics division of Johnson & Johnson, Eastman Kodak and General Motors.
“I am honored and excited to join QuidelOrtho as president and CEO during this pivotal point in the Company’s journey. The Company’s commitment to customer service and its dedication to improving healthcare outcomes align closely with my own values,” Blaser said. “I am eager to collaborate with the QuidelOrtho team to drive innovation and continued growth, while delivering value to customers, shareholders and employees.”
